A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ANA / anagrelide

[Related PubMed/MEDLINE]
Total Number of Papers: 16
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ANA  (>> Co-occurring Abbreviation)
Long Form:   anagrelide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. eGFR, ET, IQR, OR
2019 Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets. ET, FAK, MPV, PLPs
2019 Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases. AEs, CF, CP, ET, HC
2019 PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth. FDA, PDE3A
2019 [Takotsubo cardiomyopathy developing during anagrelide therapy in a patient with essential thrombocythemia]. ET, Tako
2018 Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. AML, ET, HC, SIRs
2017 Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. ADM, ECs, ET, ET-1, HU, MPs, NO, PLT
2017 Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. ALK, ET, HU, IFN, SMs
2016 The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. ET, HC, IFN, MPN
10  2015 Advances and challenges in the management of essential thrombocythemia. CV, ET, HC, IFN, MF, WBC, WHO
11  2015 Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. CV
12  2012 Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. BMMCs, ET, HU, MKCs
13  2006 Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. HC
14  2006 Effects of anagrelide on megakaryopoiesis and platelet production. BM, ET, HU
15  2005 Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. HU
16  2005 Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. ET